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Abstract [limit 300 words; currently 289] 
Introduction: Rheumatic diseases are autoimmune, inflammatory diseases often 
associated with cardiovascular disease, a major cause of mortality in these patients. In 
recent years, treatment with biologic and targeted synthetic disease modifying anti-
rheumatic drugs (DMARDs), either as monotherapy or in combination with other drugs, 
have become the standard of treatment. In this systematic literature review, we evaluated 
the effect of treatment with biologic or targeted synthetic DMARDs on the cardiovascular 
risk and outcomes in these patients.  
Methods: A systematic search was performed in MEDLINE, EMBASE, the Cochrane 
Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews for 
articles reporting on cardiovascular risk and events in patients with rheumatic disease 
treated with a biologic agent or tofacitinib. Articles identified were subjected to two 
levels of screening. Articles that passed the first level based on title and abstract were 
assessed on full-text evaluation. The quality of randomized clinical trials was assessed by 
Jadad scoring system and the quality of the other studies and abstracts was assessed using 
the Downs and Black instrument. The data extracted included study design, baseline 
patient characteristics, and measurements of cardiovascular risk and events.  
Results: Of the 5722 articles identified in the initial search, screening yielded 105 unique 
publications from 90 unique studies (33 clinical trials, 39 prospective cohort studies, and 
an additional 18 retrospective studies) that reported cardiovascular outcomes. A risk of 
bias analysis for each type of report indicated that they were of good or excellent quality. 
Importantly, despite some limitations in data reported, there were no indications of 
significant increase in adverse cardiovascular events in response to treatment with the 
Draft Revision 1.0  Nurmohamed, et al. 
  Drug Safety   
agents evaluated. Conclusions: Treatment with biologic or targeted synthetic DMARDs 
appears to be well tolerated with respect to cardiovascular outcomes by these patients. 
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Key Points [3-4 bullets] 
 This systematic literature review evaluated 105 publications from 90 unique studies 
reporting cardiovascular outcomes in response to treatment with biologic or targeted 
synthetic DMARDs. 
 There were no indications of significant increase in adverse cardiovascular events in 
response to treatment with the agents evaluated. 
 Treatment with biologic or targeted synthetic DMARDs appears to be well tolerated 
with respect to cardiovascular outcomes by these patients. 
 The conclusions in this review need to be interpreted with caution as quality and 
quantity of data vary substantially between the various drugs included, thereby 
limiting stringent comparisons. 
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1. Introduction 
Rheumatic diseases are systemic, autoimmune, inflammatory diseases characterized by 
chronic severe pain and progressive swelling and destruction of joints resulting in 
functional impairment, disability, reduced quality of life, and even death [1]. Rheumatic 
diseases are often associated with other comorbidities, the most common of which is 
cardiovascular disease (CVD), a major cause for mortality in these patients [2, 3]. 
Clinical disease activity and systemic inflammation, as evidenced by increase in specific 
biomarkers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), 
are strong predictors of increased risk of CVD [2-5], subsequent development of CVD [6, 
7], and CVD-related death [2, 3, 8]. A recently published meta-analysis showed that the 
relative risk for myocardial infarction (MI) was significantly increased in patients with 
rheumatoid arthritis (RA) and psoriatic arthritis (PsA) [9]. 
Over the last decade, biologic disease modifying anti-rheumatic drugs 
(bDMARDs), most notably tumor necrosis factor inhibitors (TNFi), and more recently, 
targeted synthetic disease modifying anti-rheumatic drugs (tsDMARDs), either as 
monotherapy or in combination with other drugs, have become the standard of treatment 
for most rheumatic diseases [10, 11]. The drugs included in this review have been 
approved for the treatment of RA (abatacept, adalimumab, certolizumab pegol, 
etanercept, golimumab, infliximab, rituximab, tocilizumab, and tofacitinib), PsA 
(abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, 
secukinumab, and ustekinumab), ankylosing spondylitis (AS; adalimumab, certolizumab 
pegol, etanercept, golimumab, infliximab, and secukinumab), and juvenile idiopathic 
arthritis (JIA; abatacept, adalimumab, etanercept, and tocilizumab). These medications 
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have been key to reducing disease activity and improving patient quality of life [10, 11]. 
However, their impact on the risk for CVD, the primary driver of mortality in these 
patients, is still unclear and needs to be evaluated given the increasingly widespread use 
of these agents. In particular, the reports of unwanted effects on lipid profiles need to be 
assessed with respect to effect on risk for CVD. 
The overall objectives of this systematic literature review were to assess and 
compare the effect of the different agents on cardiovascular (CV) events or risk outcomes 
and to assess differences in these outcomes according to patient and disease type. 
2. Methods 
A systematic literature review was performed according to Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) statement [12] (Appendix A) to 
identify studies that investigated CV risks or events in patients with rheumatic diseases 
treated with bDMARDs or tsDMARDs approved for the treatment of rheumatic diseases, 
prescribed either as stand-alone therapy or in combination. 
2.1. Data sources and searches 
The data sources searched included Medline, Embase, the Cochrane Central Register of 
Controlled Trials, and the Cochrane Database of Systematic Reviews. Databases were 
searched using specific search strings, which included synonyms and combinations of the 
following key terms: RA, JIA, PsA, AS, adalimumab, etanercept, infliximab, 
certolizumab, golimumab, tofacitinib, methotrexate, DMARDs, biosimilars, and CV risk 
factors or outcomes. The full search strings used for the electronic databases and 
conference proceedings, including all the search terms and the relationships between the 
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search terms are listed in Electronic Supplementary Material #1. Additional studies were 
identified from previously published SLRs or from the references of included studies. 
Searches were restricted to English language and limited to the time frame of January 
2000 to December 2015. 
2.2. Study selection 
All randomized and non-randomized control trials and observational studies on adult 
patients diagnosed with RA, AS, PsA, and patients of any age diagnosed with JIA were 
included. Preclinical (animal) or studies that pooled data from different agents, case 
reports, case series, case studies, previously published systematic literature reviews, 
letters, commentaries, and editorials were excluded. Also excluded were studies that 
examined the effect of bDMARDs and tsDMARDs on CV risk and events but provided 
insufficient data to interpret findings, studies with a sample size of fewer than 30 patients, 
and studies assessing novel CV biomarkers not in routine clinical use. 
2.3. Screening 
Two levels of screening were performed. In Level I, studies were identified based on title 
and abstract by SL, eliminating all publications with duplication of study populations. CJ 
performed a quality check of 10% of all screened studies. Discrepancy ≥5% would have 
prompted a re-evaluation of the whole data set. All authors reviewed all studies that were 
eligible for Level II screening. In Level II, qualifying articles identified in Level I were 
assessed based on the full-text by following a standard hierarchy of evidence. 
Publications not meeting the inclusion criteria were excluded. CJ screened 20% of the 
publications excluded at the Level II screening stage and also reviewed all publications 
determined to be eligible for inclusion. All disagreements were resolved by consensus.  
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2.4. Data extracted 
For each publication, the data was extracted by SL and reviewed by all authors. The 
information extracted included study design, baseline patient characteristics, CV risk 
profile, CV risk factors, CV events, and other observations, including CRP levels and 
lipid levels, where available, reported in patients with rheumatic diseases treated with 
bDMARDs or tsDMARDs. Blood lipid levels included total cholesterol (TC), low-
density lipoprotein cholesterol (LDLc), high-density lipoprotein cholesterol (HDLc), 
triglycerides (TG), apolipoprotein A1 (Apo-A1), apolipoprotein B (Apo-B), and 
atherogenic index (ratio of TC to HDL). CV events extracted included MI, stroke, venous 
thrombotic events (VTE), heart failure (HF), pulmonary thromboembolism, and 
hypertension. Traditional, novel and disease-specific CV risk factors or markers of 
atherosclerosis used in disease diagnosis, included augmentation index (AIx), AIx 
normalized for a heart rate of 75 beats/minute (AIx@75), cardio-ankle vascular index 
(CAVI), carotid intima-media thickness (cIMT), pulse wave velocity (PWV), systolic and 
diastolic blood pressure (BP), arterial stiffness, and N-terminal pro-brain natriuretic 
peptide (NT-proBNP). CV risk scores included the Reynolds, Systematic COronary Risk 
Evaluation (SCORE), and Framingham risk scores. All CV-related mortality was also 
extracted. 
2.5. Risk of bias 
The quality of RCTs was assessed using recommendations from the National Institute for 
Health and Clinical Excellence (NICE) single technology appraisal (STA) manufacturer’s 
template. Randomized controlled trials (RCTs) were evaluated using the Jadad scoring 
system [13] which ranges from 0 (very poor study) to 5 (rigorous study). The quality of 
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all non-randomized controlled trials (nRCTs) and observational studies were assessed 
using the Downs and Black instrument [14] which consists of a checklist of 27 items; the 
score can range from 0 (very poor study) to 32 (rigorous study). Abstracts from 
conference proceeding were assessed using the modified-Downs and Black instrument 
[15] which also consists of a checklist of 27 items; however, the score ranges from 0 
(very poor study) to 28 (rigorous study). 
3. Results 
3.1. Search 
The searches of the various databases yielded 5722 articles of which 5123 were unique 
(Figure 1). After the Level I screening of title and abstracts, 344 articles met the 
inclusion criteria and 4779 articles were excluded. Level II screening of these articles 
based on full text analysis yielded 196 relevant articles with 148 being excluded for 
various criteria (Figure 1). A deeper analysis of these showed that 41 articles had 
insufficient CV data to interpret findings, 26 articles reported on novel CV biomarkers 
that were not used in routine clinical practice, and 24 articles had enrolled <30 patients in 
the studies, leaving 105 unique publications reporting results from 95 studies. 
3.2. Risk of bias analysis 
The mean Jadad score for the 22 RCTs with full publications was 3.9 with 19 (86.4%) 
studies being of good quality. Of the 22 studies, 13 (59.1%) scored excellent with a mean 
Jadad score of 4.6, and six (27.3%) scored good with a mean Jadad score of 3.2; 3 
(13.6%) studies scored poor with a mean Jadad score of 2.0. The mean Downs and Black 
quality assessment score for the 44 nRCTs with full publications was 15.5 with 98% of 
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the studies being good or excellent quality. The mean modified Downs and Black quality 
assessment score for the 24 abstracts from conference proceedings was 5.5 with 75% of 
the published abstracts being of good quality. 
3.3. CV Risk in RA 
3.3.1. Study Characteristics 
The characteristics of all the studies classified by type for all therapeutic agents are given 
in Electronic Supplementary Material #2 Table 1. There were a total of 25 RCTs, 32 
prospective cohort studies, and 16 retrospective cohort studies. The number of patients 
enrolled in these studies ranged from 30 to 68,447. Treatment duration depended on the 
therapeutic agent being evaluated and ranged from 6 weeks to 624 weeks. 
3.3.2. Patient Characteristics 
The characteristics of all RA patients enrolled in these studies for all therapeutic agents 
evaluated are summarized in Electronic Supplementary Material #2 Table 2. Briefly, all 
patients enrolled in these studies were adults (range 38.0 years to 62.7 years), mostly 
female (range 40.8% to 100%), and had moderate to severe disease with disease duration 
ranging from 0.3 years to 17.6 years. 
3.3.3. CV Risk analysis 
The results of CV risk analysis for all therapeutic agents are summarized in Table 1. 
Overall, in patients with RA, there is a higher prevalence of HF, increased incidence of 
impaired myocardial and longitudinal deformation, and increased left ventricle 
circumferential apical strain. The findings for each drug are given in brief. 
3.3.3.1. Abatacept 
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Data on patients with RA treated with ABA were obtained from one RCT (conference 
abstract) [16], one prospective cohort (PC) study (full-length article [17] and conference 
abstract [18]), and 6 retrospective cohort (RC) studies (all conference abstracts) [19-25]. 
There were no changes from baseline reported for TC [16, 17, 21, 23, 25] and TG [17, 
21, 23, 25]. Saito et al reported increase in both HDLc and LDLc [24], but two other 
studies reported no significant change [17, 21, 23, 25]. There was no significant effect on 
BP [17], atherogenic index [16], augmentation index [16-18, 21, 23, 25], CAVI [18], 
cIMT [16], and carotid artery plaques [16]. Kume et al. reported significant reduction in 
CRP [16], but Provan et al. reported that there was no effect [17]. For patients with RA 
treated with ABA, the rate of CV events was estimated at 3.3 per 100 patient years (PY) 
[19] and the hazard ratio (HR) range was 1.0 – 1.6 relative to the comparator drug after 
adjusting for potential confounding factors [19, 20]. The Framingham 10-year CVD risk 
was significantly reduced from 12.7 to 10.6 (p = 0.011) [22] and the adjusted Reynolds 
risk score was 0.4 [21, 23, 25]. 
3.3.3.2. Adalimumab 
Data on patients with RA treated with ADA were obtained from five RCTs (four full-
length articles [26-29] and three conference abstracts [30-32]), five PC studies (four full-
length articles [33-36] and one conference abstract [37]), and six RC studies (four full-
length articles [38-41] and two conference abstracts [19, 24]). There was no effect on TC 
[27, 33, 36, 40] or TG [33, 36, 40]. In some studies, there were significant increases in 
HDLc [24, 26, 29, 32] and LDLc [24, 26, 32], but there were others that reported no 
significant change in these lipids [33, 36, 40]. There was significant reduction in CRP 
[27, 33, 36], augmentation index [27, 30], CAVI [27, 30], SAA [26, 32], sPLA2 [26, 32] 
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and arterial stiffness [30]. There were no significant effects on cIMT [27, 36], BP [34, 
36], ApoB:ApoA-1 ratio [33], or atherogenic index [27, 30]. The rate for MI was 0.3% – 
0.6% and stroke 0.3%. The rate of CV events was 2.7 per 100 PY [19] and the rate of 
VTE was 0.3 per 100 PY [35]. The rate of thromboembolic events was greater in patients 
who developed ADAb at 2.7 per 100 PY compared with 0.8 per 100 PY for patients who 
did not develop ADAb [39]. The HR range was 0.8 – 1.8 relative to rituximab or non-
biological disease modifying anti-rheumatic drugs (nbDMARDs) after adjusting for 
potential confounding factors [19, 35]. 
3.3.3.3. Certolizumab pegol 
Standard CV risk outcomes were not reported in two full-length publications from a 
single RCT and its long-term extension on patients with RA treated with certolizumab 
pegol [42, 43]. However, the prevalence of hypertension was estimated to be 8.2% – 
10.2%. The total of 11 deaths, six occurring in the first 12 months and five in the second 
12 months corresponded to a rate of 0.73 per 100 PY. None of the deaths were considered 
related to treatment with CZP. 
3.3.3.4. Etanercept 
Data on patients with RA treated with ETN were obtained from three RCTs (two full-
length articles [27, 44] and one conference abstract [30]), five PCs (all full-length 
articles) [35, 45-48], and five RCs (four full-length articles [38, 49-51] and two 
conference abstracts [19, 52]). Treatment with etanercept increased HDLc [45, 47, 48], 
but had no significant effect on LDLc or TG [45, 47]. Etanercept had a favorable effect 
on lipid profile based on a significantly lower ApoB:ApoA-I ratio, but primarily in 
patients exhibiting good or moderate response [47] according to the European League 
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Against Rheumatism (EULAR) criteria [11]; however, TC was increased significantly in 
these patients whereas there was no statistical difference in EULAR non-responders nor 
in other studies [27, 48]. Arterial stiffness [30], augmentation index [27, 30, 45, 46], 
DAS28 [45], CAVI [27, 30], CRP [27, 45, 46, 48], and left ventricle mass index [45] 
were reduced significantly in patients treated with etanercept. Small increases in CV-
associated SAEs such as HF, CAD, MI, and cerebrovascular events, were reported in 
patients with diabetes and/or chronic pulmonary disease as comorbidities [44]. Overall, 
there was a reduced risk of HF in patients treated with etanercept [49, 51], and the rates 
of CV events and serious CV events were 3.0 per 100 PY [19] and 1.0 per 100 PY [50, 
52], respectively. The risk of first VTE was 0.3 per 100 PY and the adjusted HR was 1.8 
relative to nbDMARDs [35]. 
3.3.3.5. Golimumab 
There is sparse information on the effect of golimumab treatment on CV events. What is 
available was reported in a conference abstract on data obtained from five clinical trials 
[53]. The rates of CV SAEs and ischemic CV events were reported at 0.25 per 100 PY 
and 0.43 per 100 PY, respectively. 
3.3.3.6. Infliximab 
Data on patients with RA treated with INF were obtained from four RCTs (three full-
length articles [54-56] and two conference abstracts [57, 58]), 11 PCs (11 full-length 
articles [35, 59-68] and one conference abstract [69]), and 5 RCs (four full-length articles 
[38, 49, 51, 70] and one conference abstract [19]). Data from several studies showed that 
treatment with infliximab resulted in significant increase in TC [54, 57-63, 65, 67, 68, 
70], HDLc [57-65], and TG [61, 63, 65, 70]. Results with LDLc and atherogenic index 
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were mixed. In three PC studies, there was significant increase in LDLc for at least the 
first 12 weeks [60, 61, 64], whereas data from two RCTs [54, 57, 58] and two PC studies 
[65, 67, 68] showed no significant change. Significant improvement in atherogenic index 
was reported in one RCT [57, 58], but significant worsening was reported three PC 
studies [61, 63, 65], and no significant change was reported in one RCT [56] and two PC 
studies [59, 60]. Several studies reported significant reduction in inflammation as 
determined by decreased CRP levels [56, 60, 64, 67, 68, 70]. In one RCT [55], 
augmentation index worsened in response to INF treatment, but showed no significant 
change in another [56]. Treatment with INF resulted in higher aortic stiffness index, 
aortic strain, and aortic distensibility [69], but a lower risk of HF [51], decreased arterial 
stiffness as indicated by decreased PWV [56], and decreased aortic beta index [69]. There 
were no changes reported in BP and cIMT. Long-term treatment may improve 
myocardial deformation and normalize left ventricular torsion [67, 68]. Insulin resistance 
[57, 58], HOMA-IR [57, 58], and aortic elasticity [69] all improved with INF treatment. 
There was no significant change in N-terminal pro-brain natriuretic peptide [57, 58, 63]. 
SAEs were reported in 68.2% of patients who experienced CVD-related mortality [66]. 
The rates of CV events and VTE were 2.1 per 100 PY [19] and 0.5 per 100 PY [35], 
respectively. The adjusted HR for CV events was 1.1–1.3 relative to rituximab or 
nbDMARDs [19, 35]. 
3.3.3.7. Rituximab 
Data on patients with RA treated with RTX were obtained from six PC studies (four full-
length articles [17, 71-73] and two conference abstracts [74, 75]) and four RC studies 
(two full-length articles [28, 76] and six conference abstracts [19-21, 23, 25, 31]. There 
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was no significant effect on LDLc [17, 21, 23, 25, 71-74], TG [17, 71-74], augmentation 
index [17, 71, 72], PWV [17], or systolic BP [17]. Significant increases in TC, HDLc, 
and decrease in atherogenic index were reported in two PC studies [71, 74] and no 
significant change in three PC studies [17, 72, 73] and one RC study [21, 23, 25]. 
Significant decrease in CRP was reported in two PC studies [71, 74], whereas no 
significant change was reported in another [17]. In addition, there were significant 
decreases in ESR and DAS28 [74]. The rate of MI, the most common cardiac AE [28, 31, 
76], was 0.39–0.6 per 100 PY [28, 31, 75, 76], and similar to that in the general RA 
population (0.48–0.59 per 100 PY) [28, 31, 76]. The overall rate of CV events was 2.4 
per 100 PY. However, there were more CV-related deaths among patients treated with 
rituximab than those treated with placebo for over 11 years [28, 31, 76]. The rates of 
stroke, pulmonary embolism, DVT, and death per 100 PY were 0.5, 0.3, 0.4, and 1.6, 
respectively [75]. The adjusted HR for CV events was 1.0 relative to abatacept [19, 20] 
and the adjusted Reynolds risk score was 0.1 [21, 23, 25]. 
3.3.3.8. Secukinumab 
In the two conference abstracts from a single RCT [77, 78], there were no significant 
changes in TC, HDLc, LDLc, atherogenic index, ApoB:ApoA-1 ratio, and no CV events 
reported. 
3.3.3.9. Tocilizumab 
Data on patients with RA treated with TCZ were obtained from 10 RCTs (seven full-
length articles [26, 27, 79-83] and five conference abstracts [16, 30, 32, 84, 85]), seven 
PC studies (six full-length articles [17, 37, 72, 86-88] and one conference abstract [89]), 
and six RC studies (one full-length article [90] and seven conference abstracts [20-25, 
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91]). Most studies reported significant increases in TC [16, 21, 23, 25, 27, 79-81, 83-86, 
90, 91], HDLc [22, 24, 26, 32, 79, 85, 92], LDLc [21, 23-26, 32, 81, 85, 92], and TG [21, 
23, 25, 79, 86, 92], although two PC studies reported no significant change from baseline 
[17, 72] and one RCT reported that the increase in TC was reversible [79]. When 
measured, there was significant reduction in CRP levels [16, 17, 27, 80, 84, 90], CAVI 
[16, 27, 30], atherogenic index [79], augmentation index [16, 22, 27, 30], and 
Framingham 10-year CVD risk [22]. There were no changes reported in cIMT [16, 27] or 
BP [17]. Compared with patients treated with methotrexate, hypertension and vascular 
disorders were more common in patients treated with tocilizumab [81]. The rates per 100 
PY of serious cardiac dysfunction, HF, ischemic heart disease, MI, angina pectoris, 
stroke, and death were 1.11, 0.47, 0.43, 0.09–0.2, 0.16, 0.15, and 0.07, respectively [88]. 
The rates of cardiac AEs, CV-related death, and cerebrovascular-related death were 0.4% 
[80, 84], 6.7%–9.0% [80, 84, 88], and 5.6% [88], respectively, both higher than the rates 
for patients receiving placebo (0.2% and 5.1%, respectively) [80, 84]. The proportion of 
patients with serious cardiac dysfunction did not increase over time with treatment [88]. 
The adjusted HR was 0.4 [87]. 
3.3.3.10. Tofacitinib 
Data on patients with RA treated with TOFA were obtained from nine RCTs (nine full-
length articles [29, 83, 93-99] and two conference abstracts [100, 101]). Most studies 
reported significant increases in TC [83, 93, 95, 98, 99], HDLc [29, 83, 93-101], LDLc 
[29, 83, 93-101], and TG [83, 97, 100, 101], and a significant decrease in CRP [95, 97, 
100, 101]. Treatment with statin can normalize cholesterol levels. There were no changes 
in atherogenic index [83, 93] and BP [95].  
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3.4. CV Risk in PsA 
3.4.1. Study Characteristics 
The characteristics of all the studies classified by type for all therapeutic agents are given 
in Electronic Supplementary Material #2 Table 3. There were a total of three RCTs [102-
105], two PC studies [62, 106], and two RC studies [41, 107]. The number of patients 
enrolled in these studies ranged from 60 to 23,458. Treatment duration depended on the 
therapeutic agent being evaluated and ranged from 24 weeks to 624 weeks. 
3.4.2. Patient Characteristics 
The characteristics of all PsA patients enrolled in these studies for all therapeutic agents 
evaluated are summarized in Electronic Supplementary Material #2 Table 4. Briefly, all 
patients enrolled in these studies were adults (range 42.5 years to 49.6 years), the 
proportion of female patients ranged from 29.8% to 60.0%, and the disease duration 
ranged from 0.9 years to 14.6 years. 
3.4.3. CV Risk analysis 
Overall, all PsA patients have higher prevalence of CV comorbidities including diabetes 
and hypertension than the general population [105]. Furthermore, women have higher CV 
risk compared with men, due to higher prevalence of metabolic syndrome and elevated 
BP [105]. There were no studies reporting CV events or biomarkers for patients with PsA 
treated with abatacept, certolizumab pegol, golimumab, rituximab, tocilizumab, or 
tofacitinib. The results of CV risk analysis for all therapeutic agents are summarized in 
Table 2. 
3.4.3.1. Adalimumab 
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Data on patients with PsA treated with ADA were obtained from two RC studies, both 
full-length articles [41, 107]. Costa et al. reported that HDLc was increased and TG was 
decreased [107]. Burmester et al. reported that the rate of CHF per 100 PY was zero. 
3.4.3.2. Etanercept 
Data on patients with PsA treated with ETN were obtained from one full-length article on 
a retrospective analysis of data from a RCT [105], one PC study (conference abstract) 
[106], and one full-length article for a RC study [107]. There was a significant increase in 
HDLc [105, 107], although the PC study reported no change [106]. There was significant 
reduction in CRP [105, 106]. Costa et al. reported decrease in TG [107], but the other two 
studies reported no significant change [105, 106]. There were no significant effects on 
TC [105], LDLc [105, 106], atherogenic index [106], or ApoB:ApoA-1 ratio [105, 106]. 
However, the favorable CV effects could not be attributed to lipid profile [106]. 
3.4.3.3. Infliximab 
In the single prospective cohort study evaluating the effect of infliximab treatment on CV 
risk factors in patients with PsA [62], there was a sustained increase in TC and HDLc, but 
no significant effect on LDLc or TG. There was also a significant decrease in atherogenic 
index and CRP levels.  
3.4.3.4. Secukinumab 
Among patients treated with secukinumab, the reported incidence rate for major cardiac 
AEs was 0.7 per 100 PY based on data from a single clinical trial [103, 104]. No other 
CV-related events or biomarkers were reported. 
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3.4.3.5. Ustekinumab 
In patients treated with ustekinumab, as reported in a conference abstract on a single 
clinical trial [102], the rate of major CV AEs was 0.7 per 100 PY. No other CV-related 
events or biomarkers were reported. 
3.5. CV Risk in AS 
3.5.1. Study Characteristics 
The characteristics of all the studies classified by type for all therapeutic agents are given 
in Electronic Supplementary Material #2 Table 5. There were a total of two RCTs [108-
110], eight PC studies [54, 55, 62, 111-115], and one RC study [41]. The number of 
patients enrolled in these studies ranged from 30 to 23,458. Treatment duration depended 
on the therapeutic agent being evaluated and ranged from 7 to 624 weeks. 
3.5.2. Patient Characteristics 
The characteristics of all AS patients enrolled in these studies for all therapeutic agents 
evaluated are summarized in Electronic Supplementary Material #2 Table 6. Briefly, all 
patients enrolled in these studies were adults (range 34.2 years to 43.1 years), the 
proportion of female patients ranged from 3.1% to 46.7%, had moderate to severe disease 
with a mean Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ranging 
from 4.9 to 7.0, and disease duration ranging from 1.5 years to 13.0 years. 
3.5.3. CV Risk analysis 
The results of CV risk analysis for all therapeutic agents are summarized in Table 3. 
There were no studies reporting CV events or biomarkers for patients with AS treated 
with abatacept, certolizumab pegol, rituximab, tocilizumab, ustekinumab, or tofacitinib. 
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3.5.3.1. Adalimumab 
In a full-length article on a RC study on patients treated with ADA [41], the rate of CHF 
was reported to be 0.1 per 100 PY. No other CV events were reported. 
3.5.3.2. Etanercept 
Data on patients with AS treated with ETN were obtained from two PC [111, 112], both 
full-length articles. van Eijk et al. reported that in response to ETN, there was a 
significant increase in TC, HDLc, LDLc, and TG accompanied by a significant decrease 
in SAA particles in HDLc, atherogenic index, ApoB:ApoA-1 ratio, and CRP [111]. On 
the other hand, van Halm et al. reported that in patients treated with ETN, there were 
negative correlations between disease parameters and TC, HDLc, and TG although there 
were no significant changes in the levels of these lipids [112]. No other CV events were 
reported. 
3.5.3.3. Golimumab 
Data on patients with AS treated with GLM were obtained from a single full-length 
article on a RCT [110]. There were significant increases in TC, HDLc, and TG, but not in 
LDLc. There was also a significant decrease in CRP. There were no significant changes 
in augmentation index, BP, cIMT, and PWV. No other CV events were reported. 
3.5.3.4. Infliximab 
Data on patients with AS treated with INF were obtained from six PC studies, all full-
length articles [54, 55, 62, 113-115]. Some studies reported significant increases in TC 
[54, 62], HDLc [54, 62], and TG [54], whereas Ersozlu Bozkirli et al. reported no 
significant changes in these lipids [113]. There was no significant change in LDLc [54, 
62, 113] or augmentation index [115]. There was significant reduction in CRP [55, 62, 
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113, 115] and the Framingham 10-year CV risk [113]. The results were mixed for 
atherogenic index and BP; Spanakis et al. [62] and Ersozlu Bozkirli et al. [113] reported 
significant decrease in atherogenic index and BP, respectively, but others reported no 
significant changes in these parameters [54, 55, 115]. CV-related AEs reported included 
palpitations (11.4%), hypertension (20.0%), chest pain (2.9%), and premature ventricular 
contraction (2.9%), all of which were short term [114]. There were no long-term CV 
related AEs reported.  
3.5.3.5. Secukinumab 
The clinical trial evaluating the effect of secukinumab on patients with AS [108, 109] 
reported that the exposure-adjusted incidence rate for major cardiac AEs was 0.4 per 100 
PY. No other CV events were reported. 
3.6. CV Risk in JIA 
3.6.1. Study Characteristics 
The characteristics of all the studies classified by type for all therapeutic agents are given 
in Electronic Supplementary Material #2 Table 7. There were a total of two RCTs 
(including a long-term extension) [116-119], one PC study [120], and two RC studies 
[41, 121]. The number of patients enrolled in these studies ranged from 30 to 23,458. 
Treatment duration depended on the therapeutic agent being evaluated and ranged from 6 
weeks to 624 weeks. 
3.6.2. Patient Characteristics 
The characteristics of all JIA patients enrolled in these studies for all therapeutic agents 
evaluated are summarized in Electronic Supplementary Material #2 Table 8. Briefly, the 
mean age of patients enrolled in these studies ranged from 6.9 years to 13.1 years, the 
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proportion of female patients ranged from 71.0% to 86.0%, and the disease duration 
ranged from 2.5 years to 4.7 years. 
3.6.3. CV Risk analysis 
The results of CV risk analysis for all therapeutic agents are summarized in Table 4. 
There were no studies reporting CV events or biomarkers for patients with JIA treated 
with abatacept, certolizumab pegol, golimumab, infliximab, rituximab, secukinumab, 
tofacitinib, or ustekinumab. 
3.6.3.1. Adalimumab 
The single retrospective cohort study evaluating the effect of adalimumab in patients with 
JIA reported no CHF events [41]. 
3.6.3.2. Etanercept 
Data on patients with JIA treated with ETN were obtained from one PC study (full-length 
article [120] and one RC study (conference abstract) [121]. Among children with JIA, 
treatment with ETN significantly decreased TC, LDLc, TG, and CRP, but not HDLc 
[120]. However, this overall improvement in lipid profile and inflammation did not 
translate into improvement in atherogenic index. Among adult patients with JIA who 
received ETN during childhood, the prevalence of CVD of 10.8% [121], which was 
similar to that observed in the general population. However, patients with systemic JIA 
had significantly higher rate of CVD. 
3.6.3.3. Tocilizumab 
In the CHERISH trial [116, 117], treatment with TCZ resulted in 34.6% and 11.4% 
patients having TC levels ≥170 mg/dL and LDLc levels ≥110 mg/dL, respectively. 
Levels of cholesterol exceeding the upper limit of normal for TC or LDL were observed 
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at least once in 31% of the patients who received TCZ. In the TENDER trial [118], 
patients with JIA and insulin resistance treated with TCZ showed significant reductions 
in HOMA-IR at week 6 which was associated with improvement in Juvenile Arthritis 
Disease Activity Score and active joint count. In the long-term extension study [119],  
there was no change in mean TC, but 11.9% patients reported grade 2 elevation.  
4. Discussion 
This systematic literature search for the effect of bDMARDs and tsDMARDs on CV 
events among patients with rheumatic diseases resulted in 105 publications from 95 
separate studies. The risk of bias analyses demonstrated that the methodological rigor of 
the studies included in this review was fairly high indicating that information obtained 
from these reports was reliable.  
Of the 95 studies, 73 (76.8%) included patients with RA, 7 (7.4%) included 
patients with PsA, 11 (11.6%) included patients with AS, and 5 (5.3%) included patients 
with JIA; the total is greater than 100% as some studies included multiple indications. 
The information available was heavily skewed towards CV effects in patients with RA, 
with some data published on 10 of the 11 therapeutic agents being evaluated. By 
comparison, information was available from only five therapeutic agents each for patients 
with PsA and AS, and three therapeutic agents for patients with JIA. Sufficient relevant 
data were available for only ETN for all four rheumatic diseases being evaluated; 
although data for ADA were available for all four diseases, the information was primarily 
for RA with scant information on the other three diseases. Data for INF were available 
for RA, PsA, and AS. Data on the other eight therapeutic agents were essentially limited 
to one disease, seven for RA and one (GLM) for AS. Furthermore, not all studies 
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reported the same parameters. Thus, the patchwork of data available poses a challenge 
when comparing therapeutic agents across diseases and derive definitive conclusions 
regarding their effects. 
Although the overall effects on the lipid profiles were mixed, some patterns were 
discernable. Six of the therapeutic agents (ETN, GLM, INF, RTX, TCZ, and TOFA) 
caused significant increase in TC, with an additional three (ABA, ADA, and SEC) 
indicating no change; significant decrease was only reported in patients with JIA treated 
with ETN. Significant increase in HDLc was reported for eight (ABA, ADA, ETN, GLM, 
INF, RTX, TCZ, and TOFA) of the therapeutic agents regardless of disease; only SEC 
did not increase HDLc and no data were reported for CZP or UST. The results with 
LDLc, TG, and atherogenic index were mixed depending on the study/investigators with 
about an equal number reporting significant increase or no change; significant decrease 
was only reported in patients with JIA treated with ETN. The ApoB:ApoA-1 ratio was 
significantly decreased only in patients with RA and AS treated with ETN; there was no 
effect on patients with RA treated with ADA or SEC or patients with PsA treated with 
ETN. The apparent increase in HR for CVD among patients with RA treated with 
biologics seemed counterintuitive.  Further examination of the publications revealed that 
these HRs were determined relative to a comparator biologic or nbDMARDs. Thus, these 
values do not indicate the real HRs of these drugs. Consequently, it cannot be concluded 
that there was an increase in CV risk when treated with biologics. 
Consistently, CRP was significantly decreased across eight of therapeutic agents 
(there were no data for CZP, SEC, or UST) and diseases. The data for surrogate markers 
was mixed. When reported, there was significant decrease in CAVI (ADA, ETN and 
Commented [EC1]: May be we should state that the 95% CI 
included 1. 
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TCZ, but not ABA) and augmentation index (ADA, ETN, and TCZ, but not ABA, GL or 
RTX; there was either no change or increase in response to INF treatment). There was 
generally no significant effect on cIMT or BP. 
4.1. Limitations 
The main limitation of this review is the variability in reporting of CVD events and CV 
risk factors in the publications identified. This has resulted in many gaps in data making 
it difficult for direct comparison between drugs within the same disease. Furthermore, the 
same risk factors and CV events were not reported for a given drug across all four 
rheumatic diseases making it difficult to evaluate whether or not there was a consistent 
pattern of response that could be attributed to that drug. In some cases, the only data 
available was from a published conference abstract or a single study, adding to the 
difficulty of this analysis. Thus, the conclusions drawn from this analysis need to be 
interpreted with caution. 
5. Conclusions 
There were no reports of significant increases in rates of CV outcomes when treated with 
these drugs. The data analyzed and reported in this paper indicate treatment with 
bDMARDs or tsDMARDs do not appear to be associated with adverse CV outcomes. 
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Table 1. Summary of CV risk assessment for patients with RA  
Risk Factor boDMARD tsDMARD 
ABA ADA ETN GLM INF RTX SEC TCZ TOFA 
TC ↔ ↔ ↑  ↑ ↑/↔ ↔ ↑ ↑ 
HDLc ↑/↔ ↑/↔ ↑  ↑ ↑/↔ ↔ ↑ ↑ 
LDLc ↑/↔ ↑/↔ ↔  ↑/↔ ↔ ↔ ↑ ↑ 
TG ↔ ↔ ↔  ↑ ↔  ↑ ↑ 
Atherogenic index ↔ ↔   ↑/↔/↓ ↑/↔ ↔ ↓ ↔ 
ApoB:ApoA-1  ↔ ↓    ↔ ↓ ↔ 
Systolic BP ↔ ↔ ↔  ↔ ↔  ↔  
Diastolic BP ↔ ↔   ↔     
CAVI ↔ ↓ ↓     ↓  
Augmentation index ↔ ↓ ↓  ↑/↔ ↔  ↓  
cIMT ↔ ↔   ↔ ↓  ↔  
CRP ↓/↔ ↓ ↓  ↓ ↓/↔  ↓ ↓ 
sPLA2  ↓      ↓  
SAA  ↓      ↓  
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MI  0.3%–0.6% 0.8%  0.2%   0.6%  
Stroke  0.3%      0.3%  
Carotid artery plaque ↔       ↔  
FMD  ↑        
Rate of CV SAE, per 100 PY    0.25–0.43      
Rate of CV SAE, per 100 PY    0.43      
Adjusted HR* 1.0–1.6 0.8–1.8 1.8  1.1–1.3 0.98–2.4  0.37  
Blank shaded cells indicate that data were not reported in original publications. *Relative to the comparator in that study. 
ABA abatacept, ADA adalimumab, Apo apolipoprotein, boDMARD biological originator disease-modifying anti-rheumatic drug, BP 
blood pressure, CAVI cardio-ankle vascular index, cIMT carotid inter-media thickness, CRP C-reactive protein, CV cardiovascular, 
ETN etanercept, FMD flow-mediated dilation, GLM golimumab, HDLc high-density lipoprotein cholesterol, HR hazard ratio, INF 
infliximab, LDLc low-density lipoprotein cholesterol, MI myocardial infarction, PY person year, RA rheumatoid arthritis, RTX 
rituximab, SAA serum amyloid A, SAE serious adverse event, SEC secukinumab, sPLA2 secretory phospholipase A2, TC total 
cholesterol, TCZ tocilizumab, TG triglycerides, TOFA tofacitinib, tsDMARD targeted synthetic disease-modifying anti-rheumatic drug 
↑ significantly increased, ↓ significantly decreased, ↔ no significant effect 
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Table 2. Summary of CV risk assessment for patients with PsA 
Risk Factor 
boDMARD 
ADA ETN INF SEC UST 
TC  ↔ ↑   
HDLc ↑ ↑/↔ ↑   
LDLc  ↔ ↔   
TG ↓ ↓/↔ ↔   
Atherogenic index  ↔ ↓   
ApoB:ApoA-1  ↔    
CRP  ↓ ↓   
Rate of major CV AEs, per 100 PY    0.7 0.66 
Blank shaded cells indicate that data were not reported in original publications. 
ADA adalimumab, AE adverse event, Apo apolipoprotein, boDMARD biological 
originator disease-modifying anti-rheumatic drug, CRP C-reactive protein, CV 
cardiovascular, ETN etanercept, HDLc high-density lipoprotein cholesterol, INF 
infliximab, LDLc low-density lipoprotein cholesterol, PsA psoriatic arthritis, PY person 
year, SEC secukinumab, TC total cholesterol, TG triglycerides, UST ustekinumab 
↑ significantly increased, ↓ significantly decreased, ↔ no significant effect 
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Table 3. Summary of cardiovascular risk assessment for patients with AS 
Risk Factor 
boDMARD 
ADA ETN GLM INF SEC 
TC  ↑ ↑ ↑/↔  
HDLc  ↑ ↑ ↑/↔  
LDLc  ↑ ↔ ↔  
TG  ↑ ↑ ↑/↔  
Systolic BP   ↔ ↓/↔  
Diastolic BP   ↔ ↓/↔  
Atherogenic index  ↓ ↔ ↓/↔  
ApoB:ApoA-1  ↓    
Augmentation index   ↔ ↔  
cIMT   ↔   
CRP  ↓  ↓  
SAA  ↓    
CHF per 100 PY 0.1     
Rate of major CV AEs, per 100 PY     0.4 
Blank shaded cells indicate that data were not reported in original publications. 
ADA adalimumab, AE adverse event, Apo apolipoprotein, AS ankylosing spondylitis, 
boDMARD biological originator disease-modifying anti-rheumatic drug, BP blood 
pressure, CHF congestive heart failure, cIMT carotid inter-media thickness, CRP C-
reactive protein, CV cardiovascular, ETN etanercept, GLM golimumab, HDLc high-
density lipoprotein cholesterol, INF infliximab, LDLc low-density lipoprotein cholesterol, 
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PY person year, SAA serum amyloid A, SEC secukinumab, TC total cholesterol, TG 
triglycerides 
↑ significantly increased, ↓ significantly decreased, ↔ no significant effect 
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Table 4. Summary of cardiovascular risk assessment for patients with JIA 
Risk Factor 
boDMARD 
ADA ETN TCZ 
TC  ↓ ↔ 
HDLc  ↔  
LDLc  ↓ ↑ 
TG  ↓  
Atherogenic index  ↔  
CRP  ↓ ↓ 
CHF None   
Blank shaded cells indicate that data were not reported in original publications. 
ADA adalimumab, boDMARD biological originator disease-modifying anti-rheumatic 
drug, CHF congestive heart failure, CRP C-reactive protein, CV cardiovascular, ETN 
etanercept, HDLc high-density lipoprotein cholesterol, LDLc low-density lipoprotein 
cholesterol, TC total cholesterol, TCZ tocilizumab, TG triglycerides 
↑ significantly increased, ↓ significantly decreased, ↔ no significant effect 
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Figure 1. PRISMA Flow diagram  
 
Level I, studies identified based on title and abstract; Level II, articles identified in Level 
I assessed based on full-text analysis 
Records identified through 
database searching  
Medline®: 887; Embase®: 4,511 
Cochrane Library: 324 
(n=5,722) 
Additional records identified 
through reviews and references 
(n=8) 
Records after duplicates removed  
(n=5,123) 
Records screened  
(n=5,123) 
Records excluded  
(n=4,779) 
Full-text articles and conference 
abstracts assessed for eligibility  
(n=344) 
Articles included in the 
review 
(n= 95 studies reported in 105 
publications) 
Full-text articles and conference 
abstracts excluded (n=239) 
 Full-text/original/updated 
publication currently included 
(56) 
 CV data combined for 
biologic treatment groups (32) 
 Duplicate (27) 
 No CV data of interest (15) 
 Publication not of interest (14) 
 Unable to access (4) 
Following protocol 
amendment 
 Insufficient CV data to 
interpret findings (41) 
 Novel CV biomarker (26) 
 Studies with <30 patients (24) 
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Appendix A: PRISMA Checklist 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data 
sources; study eligibility criteria, participants, and interventions; study appraisal and 
synthesis methods; results; limitations; conclusions and implications of key findings; 
systematic review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  6 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS).  
6 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, 
if available, provide registration information including registration number.  
No protocol 
exists 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics 
(e.g., years considered, language, publication status) used as criteria for eligibility, giving 
rationale.  
7 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched.  
6 
Search  8 Present full electronic search strategy for at least one database, including any limits used, 
such that it could be repeated.  
ESM#1 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic 
review, and, if applicable, included in the meta-analysis).  
7 
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Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators.  
7-8 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and 
any assumptions and simplifications made.  
7-8 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification 
of whether this was done at the study or outcome level), and how this information is to be 
used in any data synthesis.  
8-9 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  8 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2) for each meta-analysis.  
Not 
applicable 
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Section/topic  # Checklist item  
Reported 
on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies).  
8-9 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre-specified.  
Not 
applicable 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram.  
9 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, 
PICOS, follow-up period) and provide the citations.  
10, 17, 19, 
21 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment 
(see item 12).  
8-9 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple 
summary data for each intervention group (b) effect estimates and confidence intervals, 
ideally with a forest plot.  
10-16; 17-
19; 19-21; 
22-23 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of 
consistency.  
Not 
applicable 
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Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  8-9 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression [see Item 16]).  
Not 
applicable 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g., healthcare providers, users, and policy 
makers).  
23-25 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias).  
25 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and 
implications for future research.  
25 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of 
data); role of funders for the systematic review.  
26 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS 
Med 6(7): e1000097. doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
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